SingleFlowEx CD13 PerCP-Cy™5.5

SingleFlowEx is fluorochrome-labeled monoclonal antibody single reagent for use in laboratory-developed multicolor flow cytometry tests in order to examine human clinical samples. SingleFlowEx can be used in various multicolor combinations. Laboratory shall establish the SingleFlowEx performance characteristics in conjunction with other reagents in normal and pathological samples.

Product Specifications

Certification

RUO (GMP)

Clone

WM15

Applications

FC (QC tested)

Concentration

0.080 mg/mL

Format

PerCP-Cy.5

Buffer

Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Components

1 vial of monoclonal antibody reagent.The content (1 mL) is sufficient for min. 100 Tests.

References & Citations

*Favaloro EJ, Browning T, Facey D: CD13 (GP150; aminopeptidase-N) : predominant functional activity in blood is localized to plasma and is not cell-surface associated. Exp Hematol. 1993 Dec;21 (13) :1695-701. , URL: https://www.ncbi.nlm.nih.gov/pubmed/7902291?dopt=A, *McCormack E, Mujic M, Osdal T, Bruserud O, Gjertsen BT: Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013 Feb 14;121 (7) :e34-42. doi: 10.1182/blood-2012-05-429555., URL: https://www.ncbi.nlm.nih.gov/pubmed/23243270, *Leukocyte Typing V., Schlossman S. et al. (Eds.), Oxford University Press (1995) ., URL: , *Leukocyte Typing IV., Knapp W. et al. (Eds.), Oxford University Press (1989) ., URL: , *Leukocyte Typing III., McMichael A.J. et al. (Eds.), Oxford University Press (1987) ., URL: , *Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Musgrove E: Myeloid progenitor surface antigen identified by monoclonal antibody. Br J Haematol. 1985 Sep;61 (1) :11-20., URL: https://www.ncbi.nlm.nih.gov/pubmed/4052321?dopt=A, *Bradstock KF, Favaloro EJ, Kabral A, Kerr A, Hughes WG, Berndt MC, Musgrove E: Human myeloid differentiation antigens identified by monoclonal antibodies: expression on leukemic cells. Pathology. 1985 Jul;17 (3) :392-9. , URL: https://www.ncbi.nlm.nih.gov/pubmed/3865147?dopt=A, *Weijler L, Kowarsch F, Wödlinger M, Reiter M, Maurer-Granofszky M, Schumich A, Dworzak MN: UMAP based anomaly detection for minimal residual disease quantification within acute myeloid leukemia. Cancers (Basel) 2022 Feb 11;14 (4) :898., URL: https://pubmed.ncbi.nlm.nih.gov/35205645/, *Use of this product has not been published., URL:

Other References

*Tokuhara T, Hattori N, Ishida H, Hirai T, Higashiyama M, Kodama K, Miyake M. Clinical significance of aminopeptidase N in non-small cell lung cancer. Clin Cancer Res. 2006 Jul 1;12 (13) :3971-8., URL: https://pubmed.ncbi.nlm.nih.gov/16818694/, *Petrovic N, Schacke W, Gahagan JR, O'Conor CA, Winnicka B, Conway RE, Mina-Osorio P, Shapiro LH. CD13/APN regulates endothelial invasion and filopodia formation. Blood. 2007 Jul 1;110 (1) :142-50., URL: https://pubmed.ncbi.nlm.nih.gov/17363739/, *Terauchi M, Kajiyama H, Shibata K, Ino K, Nawa A, Mizutani S, Kikkawa F. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC Cancer. 2007 Jul 27;7:140., URL: https://pubmed.ncbi.nlm.nih.gov/17655775/